Chronic obstructive pulmonary disease (COPD) is a leading cause of global morbidity and mortality, with pharmacological management increasingly guided by precision stratification based on symptom burden, exacerbation history, and blood eosinophil count. Long-acting muscarinic antagonist (LAMA) monotherapy has established itself as the foundational bronchodilator strategy in symptomatic patients, with robust evidence for dyspnea reduction, lung function improvement, and exacerbation prevention.

Current guidelines reinforce LAMA monotherapy as an evidence-based starting point for symptomatic patients, while recommending LAMA/LABA dual bronchodilation as the preferred initial combination therapy in higher-risk or more symptomatic patients. Once-daily LAMA/LABA fixed-dose combination therapy has demonstrated superiority over either monocomponent alone and over LABA/ICS in post-bronchodilator FEV₁, exercise endurance, and patient-reported outcomes across multiple clinical programs. Critically, dual bronchodilation consistently achieved superior exacerbation rate reduction and FEV₁ benefit versus LABA/ICS in patients without qualifying eosinophil counts (≥300 cells/µL) or exacerbation history, providing robust evidence to rationalize ICS avoidance in this group. Real-world prescribing analyses continue to reveal significant overuse of LABA/ICS beyond evidence-based criteria, exposing patients to unnecessary pneumonia, osteoporosis, and metabolic adverse effects. Appropriate therapy de-escalation from ICS-containing to LAMA/LABA regimens in eligible patients remains a key implementation gap.

How do you approach the decision to escalate from LAMA monotherapy to LAMA/LABA dual bronchodilation in symptomatic COPD patients, and what clinical parameters — beyond FEV₁ and exacerbation history — most influence your escalation threshold? What barriers do you encounter when attempting to de-escalate or avoid ICS-containing regimens in stable COPD patients who do not meet evidence-based criteria for ICS use, and how do you navigate patient reluctance to change established therapy?